Skip to main content

Henderson Michael Thomas's Form 4 filing

Apogee Therapeutics, Inc. (APGE) · filed Nov 13, 2025

Accession no.
0001104659-25-111626
Filed
Nov 13, 2025
Trade date
Nov 13, 2025
Filing delay
Same day
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions. Open-market sales total $1.26M. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Henderson Michael ThomasCIK 0001779990Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 13, 2025Common StockSSaleDisposed−3,340$61.93F2−$206,846.21,289,647Direct
Nov 13, 2025Common StockSSaleDisposed−14,774$63.14F3−$932,830.361,274,873Direct
Nov 13, 2025Common StockSSaleDisposed−1,786$63.89F4−$114,107.541,273,087Direct
Nov 13, 2025Common StockSSaleDisposed−100$64.52−$6,4521,272,987Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.45 to $62.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

F3

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.50 to $63.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

F4

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.52 to $64.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)